Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

454

Figures (1-2)

103

Tables (1-5)

Sum=665

Publishing Process of This Article

Item

Count

Browse

Download

Sum=68

Dec 18, 2024 (publication date) through Feb 14, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Orthop. Dec 18, 2024; 15(12): 1155-1163
Published online Dec 18, 2024. doi: 10.5312/wjo.v15.i12.1155

Table 2 Types of immune checkpoint inhibitors used in patients (n = 28)

Type of immune checkpoint inhibitors	Number
Pembrolizumab	15
Nivolumab	2
Atezolizumab	3
Durvalumab	3
Ipilimumab	0
Pembrolizumab + atezolizumab	2
Pembrolizumab + durvalumab	1
Nivolumab + durvalumab	1
Nivolumab + ipilimumab	1

Citation: Ishibashi Y, Kobayashi H, Ando T, Okajima K, Oki T, Tsuda Y, Shinoda Y, Sawada R, Tanaka S. Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study. World J Orthop 2024; 15(12): 1155-1163
URL: https://www.wjgnet.com/2218-5836/full/v15/i12/1155.htm
DOI: https://dx.doi.org/10.5312/wjo.v15.i12.1155